Cellares Corporation
Cellares is a privately held company developing automated, end-to-end cell therapy manufacturing systems (the Cell Shuttle®) to enable scalable and reproducible production of engineered cell therapies. The company focuses on automation hardware and software to reduce manual labor and variability in autologous and allogeneic cell therapy workflows.
Layoff timeline
1 EVENTCellares Corporation plans to permanently eliminate about 100 positions effective Oct. 20, 2026, after Bristol Myers Squibb terminated a partnership alleging Cellares' automated Cell Shuttle system could not meet requirements to manufacture the CAR-T therapy Breyanzi. The layoffs were disclosed in a WARN Act filing sent to BioSpace by California’s Employment Development Department and were framed by Cellares as a response to the loss of the key contract. Cellares’ CEO noted staff reductions on LinkedIn but did not name the pharma partner or give details; the WARN filing lists a wide range of affected roles including senior staff across engineering, marketing, recruitment and software, as well as an alliance manager, a janitorial specialist and the VP of commercial operations. Cellares disputes BMS's characterization of its system and emphasized prior clinical GMP production using Cell Shuttle, while noting the company had raised $257 million earlier in its push toward commercial-scale production.
Stories from here
No one has shared a story from Cellares yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →Get alerts for Cellares
We'll email you the moment a new layoff is reported here.